Trial Profile
A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, ASCENDING MULTIPLE DOSE STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF XMAB 5871 IN PATIENTS WITH RHEUMATOID ARTHRITIS
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Obexelimab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Xencor
- 15 Nov 2023 Results of a PopPK model analysis from four clinical trials: a first-in-human, single-ascending dose study in healthy volunteers; 2) a multiple-ascending dose study in patients with RA; 3) an open-label study in patients with IgG4-RD; and 4) a PK and relative bioavailability study.
- 09 Nov 2015 According to a Xencor media release, data from this study were presented at the American College of Rheumatology (ACR) 2015 Annual Meeting.
- 26 Jun 2015 According to a Xencor media release, data from this study were presented at the European League Against Rheumatism (EULAR) 2015 Annual Meeting.